Clinical Trial Update: Orlistat Overcoming Third-generation EGFR-TKI Resistance [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating whether adding orlistat can overcome resistance to osimertinib in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Orlistat (orlistat)
• Osimertinib (osimertinib)

Snippet

Sponsor: Ping Peng | Conditions: Lung Adenocarcinoma, Osimertinib | Phase 2 | Status: NOT_YET_RECRUITING